Show simple item record

dc.contributor.authorCollins, DCen_US
dc.contributor.authorSundar, Ren_US
dc.contributor.authorLim, JSJen_US
dc.contributor.authorYap, TAen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2017-03-02T16:58:15Z
dc.date.issued2017-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/27871777en_US
dc.identifierS0165-6147(16)30156-0en_US
dc.identifier.citationTrends Pharmacol Sci, 2017, 38 (1), pp. 25 - 40en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/468
dc.identifier.eissn1873-3735en_US
dc.identifier.doi10.1016/j.tips.2016.10.012en_US
dc.description.abstractPrecision medicine continues to be the benchmark to which we strive in cancer research. Seeking out actionable aberrations that can be selectively targeted by drug compounds promises to optimize treatment efficacy and minimize toxicity. Utilizing these different targeted agents in combination or in sequence may further delay resistance to treatments and prolong antitumor responses. Remarkable progress in the field of immunotherapy adds another layer of complexity to the management of cancer patients. Corresponding advances in companion biomarker development, novel methods of serial tumor assessments, and innovative trial designs act synergistically to further precision medicine. Ongoing hurdles such as clonal evolution, intra- and intertumor heterogeneity, and varied mechanisms of drug resistance continue to be challenges to overcome. Large-scale data-sharing and collaborative networks using next-generation sequencing (NGS) platforms promise to take us further into the cancer 'ome' than ever before, with the goal of achieving successful precision medicine.en_US
dc.format.extent25 - 40en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectbiomarkeren_US
dc.subjectnext-generation sequencingen_US
dc.subjectomics technologyen_US
dc.subjectoncologyen_US
dc.subjectprecision medicineen_US
dc.subjecttheranosticsen_US
dc.subjectBiomarkers, Tumoren_US
dc.subjectBiopsyen_US
dc.subjectClinical Trials as Topicen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectHigh-Throughput Nucleotide Sequencingen_US
dc.subjectHumansen_US
dc.subjectImmunotherapyen_US
dc.subjectNeoplasmsen_US
dc.subjectPrecision Medicineen_US
dc.titleTowards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-10-19en_US
rioxxterms.versionofrecord10.1016/j.tips.2016.10.012en_US
rioxxterms.licenseref.startdate2017-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfTrends Pharmacol Scien_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume38en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
dc.contributor.icrauthorYap, Timothyen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record